Is Vitamin K Bone Health Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Vitamin K Bone Health Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Meta-regression indicated that control sample size and bisphosphonate exposure duration in MRONJ groups were associated with effect size. [Daneshvar A (2026); evidence level 1] - CONCLUSIONS: Postdiagnosis serum 25(OH)D levels appear similar in MRONJ patients and antiresorptive-exposed controls; however, the evidence is limited and of very low certainty, so conclusions should be interpreted cautiously. [Daneshvar A (2026); evidence level 1] - OBJECTIVES: To compare serum 25-hydroxyvitamin D [25(OH)D] levels between patients with medication-related osteonecrosis of the jaw (MRONJ) and antiresorptive-exposed controls. [Daneshvar A (2026); evidence level 1] - MATERIALS AND METHODS: Following PRISMA guidelines, PubMed, Scopus, Web of Science, and Embase were searched through September 2025 for studies including adults (≥ 18 years) treated with bisphosphonates or denosumab that reported 25(OH)D levels in MRONJ cases and exposed controls. [Daneshvar A (2026); evidence level 1] - Patients with type 2 diabetes mellitus (T2DM) commonly demonstrate reduced bone quality and elevated fracture risk rates despite having normal or elevated bone mineral density (BMD). [Kashmoola IO (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.